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Chapter I

HYPERTENSION
A consideration of the treat ment of hypertension at this time, in view of the uncertainties that
exist concerning the disease and the additional knowledge acquired each day through experimentation, would
be incomplete without some thought devoted to the history of the disease, theories of its etiology, its
classification, its clinical aspects, and the relationship of the kidney, which has been much stressed today.
In this thesis an · endeavor will be made to
consider the above-mentioned facts and the treatment
of hypertension as it is practiced today and to review
the literature relative to recent experimental concepts including the use of kidney extracts.
At the onset it should be understood that by
the term

11

hypertension 11 we mean essential hypertension.

It seems prudent at this time to define the term as
the existence of abnormally high systolic and diastolic arterial blood pressure in individuals who have neither inflammatory kidney disease, urinary tract obstruction or other disorders which are known to result in
elevation of the blood pressure~

With this definition

a diagnosis of essential hypertension can be correctly
made only after the known causes of hypertension have
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been excluded.

Thus we realize the difficulties to

be encountered in a discussion of the treatment of hypertension.
HISTORY - The historical development and the
concept of essential hypertension may be summed up as
2

follows:

Hypertension was formerly regarded as
alway~ being an expression of either Bright's disease (Nephritis) or arteriosclerosis. In 1874 Mahomed
described the 11 prealbuminuric stage of Bright's disease,11 a term indicating that hypertension may precede frank nephritis but not disassociating the two.
Von Basch, 1874, recognized that hypertension may
exist in the absence of nephritis and demonstrable arteriosclerosis, and attributed it when present under
these circumstances to "latent arteriosclerosis." Allbutt, 1896, differentiated hypertension (hyperpiesia)
from Bright's disease and senile arteriosclerosis.
Huchard, 1899, also recognized hypertension in the absence of Bright's disease and, to emphasize its importance in the etiology of arteriosclerosis, called it
11
presclerosis. 11 "Hypertensive cardiovascular disease"
was the designation used by Theodore Janeway in 1913,
and it became widely accepted at the time. Frank in
1911 introduced the term "essential hypertension."
Volhard and Fahr, 1914, and Keith, Wagener and Kernohan (1928), have especially directed attention to
cases of essential hypertension which are characterized by kidney involvement and a rapidly progressive,
fatal course-- 11 malignant nephroscleros1s 11 or "malignant hypertension," in contrast to the commoner, 11 benign11 disorder.
CLASSIFICATION OF HYPERTENSION
It has long been realized that devoted arterial pressure may be caused by more than one morbid
state but it is not generally recognized how numerous
and how protean these causes may be according to Page
there are 47 different causes of hypertension and he

- 2 -

groups them as follows~
RENAL (A)

Affectations of vessels
Arteriosclerosis
Periarteritis nodosa
Arterit i s
Anomaly
Obstruction (tumors aneurysm)
Arteriosclerosis, embolism, thrombosis
Thromboangitis obliterans

(B)

Affectations of Parenchyma
Acute nephritis
Chronic nephritis
Pyelonephritis
Hydronephrosis
Polyciptic disease
Amyloidosis
Infarcts
Tumors
Hypernephroma
Ectopia
Toxemia of pregnancy
X-Ray lesions
Renal stones
Hypogenesis
Dystopia

(C)

Affectations of perinephric structures
Perinephritis
Tumors
Hema'toma

(D)

Affectations of ureter
Obstruction (pelvis, ureter, prostate,
urethra)
Pyelitis

CEREBRAL Inc~ased i ntracranial pressure (trauma, tumor,
inflammation)
Diencephalic stimulation
Anxiety states
Tesions of brain stem (ascending paralysis,
poliomyelitis)
CARDIOVASCULAR Heart failure
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Arterio-v enous fistulae
Angi na pectaris
Heart black
CoartDtio n o~ aorta
At heromat osis
Lead pois oni ng
Pol yc ythei.:. i a
ENDOCRINE Phe ochromacyt oma
Adrenal carcinoma
Adrenal hyperplasia(?)
Wilma tumor
Cushings syndrome (pituitary adenoma)
Pituitary basaphilism
Acromegaly
Thymis carcinoma
Hyperthyoidism
Menopause (natural or artificial)
Orrhenoblastoma

UNKNOWN Es s ential hypertension
Malignant hypertension
It is the purpose of this thesis not to elaborate on all of the etiological factors of hypertension but to limit the subject to the last-mentioned
hypertensive states, the others being mentioned only
in passing.

This classification brings to the mind of

the reader, whereas there are many hypertensive states,
there is only one of these states in which the essential ca.use is unknown at present.

Thus, the fundamen-

tal basis for this thesis is to bring to light some of
the recent advances toward the understanding of this confusing subject.
Essential hypertension may be class i fied simply as benign and malignant hypertension; neither of
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which should be thought of as a distinct disease but
as a phase of one disease, essential hypertension.
Thus a group of patients with essential hypertension
may follow divergent courses; some remain almost asymptomatic, others will suffer apoplexy, and others heart
failure or angina pectoris.

In another group the dias-

tolic pressure rises very high and results in acute
arteriolar damage and increased intracranial pressure.
Benign and malignant hypertension may well be differentiated in terms of prognosis.

A patient afflicted with

benign hypertension may and often does live his full
span of life while in malignant hypertension the course
usually extends from a period of months to a year or two.

PATHOGENESIS
Hypertension, as is almost invariably proven
at autopsy, eventually produces a triad of lesions - cardiac hypertrophy, arteriosclerosis, and certain renal
changes.

The cardiac hypertrophy and arteriosclerosis

are common to all varieties of long-standing hypertension; the kidney changes, however, differ from those of
chronic glomerulo-nephritis.
Hypertrophy of the left ventricle is one of
the earliest changes seen in the heart.

With this com-

pensatory hypertrophy there may be an oxygen deficiency
to the thickened muscle fibers and this contributes
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to the development of left ventricular dilatation.

This

may soon be followed by left auricle hypertrophy and
dilatation.

The right side of the heart is least affec-

ted in hypertension.

Heart failure is the cause of death

in 60 per cent of patients with essential hypertension.
Arteriosclerosis is always present in longstanding cases of hypertension.

It is a common cause of

coronary thrombosis, cerebral thrombosis or hemorrhage
and death.

The most important lesion resulting from

arteriosclerosis is the arteriosclerot i c kidney.

Changes

in the large arteries are often present and may be severe.

Changes in the choroid and retina are common.

There is gene rally well-marked arteriosclerosis of the
aorta and its branches, but in other cases there is little more than the usual senile changes.

Arterioscler-

otic gangrene of the extremities is rare unless the hypertension is complicated by diabetes; arteriosclerotic
lesions of the abdominal viscera are also rare.

Often

there are arteriosclerotic thickenings of the mitral
and aortic valves.
Arteriolosclerosis is the usual finding in
the kidneys of the hypertensive.

There are varying de-

grees of parenchymal atrophy; the cortex is thin, the
arteries thickened and gaping.

Arteriolosclerosis,

with secondary hyalinization of glomeruli, tubular
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atrophy e.nd re placement f i brosis characterizes the kidney
is essential hypertension of long duration.

Death from

uremia is rare while in the malignant type, described
below, uremia is the usual cause of death, often in association with congestive heart failure and cerebral
vascular accidents.
The kidney in malignant ey.pertension presents
in addition to the findings described above, a

11

flea-

bitten" surface as a result of subcapsular hemorrhages
and a necrotizing endarteritis present in the afferent
and interlobular arterioles.

Contiguous glomeruli

may be necrotic and this is associated with degenerative
changes in the corresponding tubules which often contain
blood and debris.
SYMPTOMS
As has be~n stated, the onset of symptoms
in essential hypertension usually become manifest after the fourth decade of life.

Initial symptoms may

appear under many guises but, for the most part, the
disease runs a chronic course after an insidious onset.
Thus, symptoms of cardiac failure, of angina pectoris,
of an organic disease of the brain, of a psychoneurosis, of renal di s e a se, or of disorders of various other
organs may be manifest.

At ti mes, a fatal apoplectic

stroke may initiate the disease.
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Often, the patient may

have hade vague symptoms for years before consulting
the physician.
The early history of patients with essential
hypertension often reveals symptoms of vasomotor and
emotional instability - headache, vertigo, epistaxis,
nervousness, irritability, restlesness, asthenia, loss
of appetite, and inability to concentrate on work.
Cardiac insufficiency is a frequent initial
symptom, particularly in the obese.

Dyspnea following

exertion or meals is a frequent complaint.

Heart con-

sciousness, palpitation, insomnia, precordial oppression, swelling of the feet, nocturia, etc., may exist
for years before t here is evidence of diminished cardiac reserve or congestive heart failure.

The majority

of patients with essential hypertension eventually experience cardiac symptoms and die of hes.rt failure.
About 20 per cent of deaths in essential hypertension are due to cerebra.l thrombosis or hemorrhage,
manifestations of cerebral arteriosclerosis.

The first

symptoms may be those of facal cerebral disturbances
or mental impairment resulting from multiple areas of
softening due to cerebral arteriosclerosis.

Rarely,

transitory palsies and other man~festations of hypertensive encephalopathy are early symptoms - headache,
vomiting, convulsions, paroxysmal dyspnea, amaurosis,
aphasia, drowsiness, and coma.

- 8 -

Renal symptoms are not conspicuous; only a
small pro9 ortion of individuals with essential hypertension suffer any serious symptoms or succumb as a
result of damage to the function of the kidneys.

Noc-

turia is usually associated with the di mirnshed cardiac
reserve.

If it results from impairment of renal func-

tion, it is then accompanied by polyuria.

Uremic mani-

festations, however, do occur in the malignant phase of
the disease in younger individuals.

PHYSICAL SIGNS
Blood pressure determinations by use of the
sphygmomanometer are of paramount importance in arriving
at a diagnosis of hypertension.

Usually, the systolic

pressure is well over 160 mm. and the diastolic over 100
mm.

The height of the blood pressure varies greatly

in different cases and often in the same patient.

Var-

iations of 30-40 mm. in a single office visit are not
uncommon.

The readings most frequently encountered

are around 200 mm. systolic and 110mm. diastolic.

How-

ever, the sy stolic pressure may reach almost 300 mm.,
and rarely exceed it and the diastolic even surpass
180 mm.

In some cases the blood pressure remains for

years around 170 mm. systolic and 95-100 mm. diastolic.
The pressure may rise rapidly or more often slowly and
progressively over a period of years.
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In other instances,

the pressure changes very little from tha t found at the
first exami na tion, even though followed for years.
The only reliable physical sign of left ventr i cular hypertrophy is the heav i ng a pex-beat, which
lifts the palpating finger with abnormal ly great force.
Enlargement is us ually not demonstrable by percussion
or displacement of the apex beat to the left.

X-Ray ex-

amination does not always show this enl a rge ment.

The

electrocardiogr am , as a r ule, exhibits l eft axis deviation to gether with inverstion of the T wave in lead I.
The first apical sound 1s often l oud and booming; a diastolic shock over the aortic area and a ringing, tympanitic aortic second sound are usually present.
Changes in the fundus oculi a r e very common
and often of great -diagnostic and prognostic si gnificance in essential hypertension.

Examina tion reveals

varying degrees of a rterial tortuosity and of narrowing
of the lumina of the vessels.

The veins appear to be

cons~ricted where they are cro s sed by t he arteries.

Pap-

illedema, hemorrhage, and retinal and ch oroidal lesions
occur in the h igher pressure levels and especially in
malignant hypertension.
The pulse is hard and difficult to compress.
The bra chial, temporal and radial arteries may be conspicuously tortuous and pulsa ting.
The ur i ne may be entirely normal.
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Traces of

albumin, hyaline and finely granular casts and occasional red blood cells may be present.
usually normal.
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Renal function is

Chapter II

EXPERIMENTAL STUDIES OF THE ETIOLOGICAL
FACTORS OF ESSENTIAL HY.PERTENSION
5

In 1895, Tigerstedt and Bergman found that
a saline extract of rabbit kidneys had a prolonged
presser effect when injected into another rabbit.
They named the active ingredient of the renal extract,
renin.

Since the production of experimental renal

hypertension in recent years all of the findings of
these two men have been confirmed and extended by
a large number of investigators.
First, before going on with the work being
conducted at present on the production of hypertension
in animals by the injection of renin and the theories propounded by these investigators as to the
etiology of this condition, I had best review some
of the investigations leading up to the present concept of essential h ypertension in the human.
The finding that persiAtent hypertension may
be induced in the dog by constriction of both main
renal arteries has been confirmed by many investi6,7 , 8,9
gators . Hypertension has now been produced in the
10
11
12
monkey, rats, rabbit, goat and sheep. The development
of this method was based on the assumption that in
the most common type of hypertension in which fair-
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SU BJECT

HUMAN ESSENTIAL
HYPERTENSION

EXPER . RENAL
HYPERT ENS ION

Cardiac rate

Normal

Normal

Cardiac output

Normal

Normal

Blood volume

Normal

Normal

Viscosity

Normal

Normal

Peripheral blood flow

Normal

Normal

Sympathectomy

Does not abolish
hypertension

Does not abolish
or prevent Hyper.

Resection of splanchnic
nerves

II

II

Renal blood flow

Apparently reduced

Renal excretory function

(a) Benign phase normal Beni gn phase
normal
(b) Malignant pha s e
Malignant phase
reduced
reduced

Cardiac hypertrophy

Left ventricle when
Left ventricle
u~~omplicated by failure

Pulmonary arterial press-ure

Not altered when hyper-Unaltered
tension is uncomplicated
by left heart failure,
a s indicated by normal
right heart

Unilateral renal disease
associated with hyperten- sion

Cured by nephrectomy
Cured by nephwhen proved unilateral rectorny

Bilateral nephrectomy

No rise of pres sure

Thyroidectomy

Does not preDoes not prevent or
cure hypertens i on un- vent or abolless of the type as- ' ish hypertension
sociated with d~eease
of thyroid

Generalized arteriolar
necrosis and necrotizing
arteriolitis

In mali gnant phase
only

Reduced

No rise of
pre,s sure

In malignant phas e
only---39

ly widespread vascular disease is almost an invariable accompaniment, the arteriosclerosis of the
kidney is the prima ry condition which in some vey
controls the blood pressure.

The resultant experi-

mental hypertension is strong indication that in
man, too, the elevation of the blood pressure may
be due to renal vascular disease or any other kind of
renal disease which might produce a similar effect on
the renal circulation.
The various studies on experimental renal
hypertension produced by constriction of the main
renal arteries show clearly that the two are practically one and the same.

In the table on the oppo-

site page the similarities are briefly summarized.
Much evidence has now accumulated which,
both directly and indirectly, shows that the elevat~
ion of the blood pressure is due to a humaral mechanism and not due to increased peripheral resistance.

It has been shown, for example that renal
13
denervation, bilateral suprodiaphragmatic excision
of splanchnic nerves and lower four thoracic sym14
pathetic ganglia, subdiaphragmatic splanchicetomy
8

with excision of celiac and upper lumbar ganglia,
bilateral section of anterior nerve roots from sixth
15
dorsal to second lumbar inclusive, destruction of
16
the spinal cord, and complete sympathectomy, in17
eluding denervation of the heart, neither prevent
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nor abolish the hypertension which results from constriction of the main renal arteries.
a

This eliminates

nervous mechanism as the cause of hypertension and

points in the direction of a humeral mechanism as
the cause.
One of the direct indications that a humoral mechanism is involved in the pathogenesis of
.
18
experimental renal hypertension is the finding that if
the renal veins are obstructed at the same time the
renal arteries are constricted no use in pressure
occurs.

Another piece of evidence is the finding

that if the kidneys are tr~nsplanted to the neck
or groin with no nervous connections to it and the
19,8
renal arteries constricted a rise in pressure occurs.
20

Likewise, the demonstration that the transplantation of an ischemic kidney from one dog to the neck
of a nephrectomized dog causes an immediate and sustained rise in blood pressure as soon as blood is
allowed to flow through the anRstomosed vessas, indicates that some substance is washed from the kidney
into the systemic circulation.

Finally, the actual

demonst~ation of a vasoconstrictor and pressor substance in the blood from a kidney with its main artery
constricted whether constriction is acute or chronic,
is proof of the existence of a humeral mechanism.
The fact that renal excretory function re-
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12
mains normal in benign experimental renal hypertension

indicates tha.t the retention of nitrogenous metabolites is not a causative factor.

Also the observa-

tion that bilateral nephrectomy, which results in
27

azatemia, causes no elevation of blood pressure is aditional proof that retention of nitrogenous waste
products does not cause increase in blood pressure
but indicates that the presence of the kidneys in the
body is necessary for elevation of blood pressure.
As mentioned before, Tigerstedt and Bergman discovered renin and found it was a protein,
not dialzable and d,~ stroyed by heat.

They found that

it had a greater and more prolonged presser effect
when injected into a bilRterally nephrectomized animal and that when renin was injected repeatedly, with
intervals of only a few minutes between injections,
it elicited decreasing responses of the blood pressure and event ually no response.

However, they came

to the conclusion that renin acted directly on peripheral blood vessels.

These results of Tigerstedt

and Bergman have been confirmed except that it has
been found renin does not act directly on the p~ripheral blood vessels for the presser response to
an intravenous injection of renin is not associated
with a decrease in peripheral blood flow or a fall
?,3

in skin temperature.
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Out of recent investigations it has been
discovered that renin 1s not a direct presser substance and is not effective unless injected intravenously .

This was a stumbling block for awhile

to the proper understanding of the mechanism of
the pressor effect of renin when injected intrav24

enously.

Friedman, Abramson and Marx indicated

the answer to this problem for they . found that when
an isolated dog's tail was perfused with Tyrode 1 s
solution and renin no vasocanstriction occurred but
when blood plasma and renin was perfused through
the isolated tail, vasocanstriction occurred.

This

observa tion was confirmed by Page and his collabor25,26 ,
2?
ators, and by a group of South American workers.
Page and his collaborators gave the name "reninact1vator" to the substance in the blood which interacts with renin and called the resultant vasoc28

onstrictor and presser substance "angiotonin".

The

South American workers named the substance in ue
blood "hypertensin-precursor" and the vasoconstr i c27
tor and presser substance "hypertensin".
The phenomenon of tachyphylactis, the name
to which Tigerstedt and Bergman earlier had giim
the condition of decreasing responses of the blood
pressure to renin in an animal when thi s substm ce
was inject~d repeatedly with a few minutes between
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injections, has been investigated thoroughly by
29

2?

Page and the South American Workers.

They came to

the conclusion that the reason for the progressive
decrease in response to consebutive inje~tions of
renin was due to the exhaustion of renin-activator in the · blood.
Even more direct evidence as to the role
of renin in initiating the rise of blood pressure
'

which follows constriction of the renal arteries
is to be found in the demonstration that extracts
of kidneys of animals with chronic renal hyperten30

31

sion and those with complete renal ischemia contain more renin than extracts of the opposite normal kidneys.

However, the demonstration of renin

in the blood of the renal vein and the systemic
blood of animals made hypertensive by the constriction of the main renal arteries is direct proof
that renin initiates the - rise in blood pressure.
As already mentioned both Page and his
co-workers and the South American group agree ~hat
there is a substance in the blood stream upon
which renin acts - the former given the name P~eangiotonin to this substance and the latter using
the term Pre-hypertension to describe it.

They al-

so agree that it is by the interaction of these
two substances that the final vasoconstrictor and
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~

presser substance is produced.

However, at the

present time this final vasoconstrictor and pres32

sor substance, named Angiotonin by Page and Hypertensin by the South American group, has not been
isolated from the systemic blood circulation of
patients with essential hypertension or animals
with experimental hypertension.
Both Page and Co-workers and Braun-l~nendez and his co-workers agree upon the identity
of the properties of renin-activator.

It has been

found to be a protein, in all probability a pseudoglobulin ~ince it is soluble in distilled w~er
and is precipitated from blood serum between 6.34
and 0.6 saturation with ammonium sulfate.

It ls

heat labile, non-dialyzable, not ultrafiltrable
27

and is present in blood serum and red blood cells.
It has been found to be undiminished following hy33

pophysectomy but some have found that it -decreases
and finally disappears from the systemic blood of
untreated adrenolectomized male dogs.

Adequate

therapy with adrenal cortical harmones results 1n
34

a return of preangiotonin to the normal level.
Page failed to find any effect exerted on preangiotonin by bilateral adrenalectomy, but he recently
has found that it disappears from the blood when
the liver is removed or severly damBged by n hepa35

totoxic substance.
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The South Americans found that the reaction between renin and hypertensin precursor (prehypertensin) is rather specific in that the effect
of renin on the substrate in the blood could not
be produced by other enzymes such as pepsin, pancreatin, papain, etc.

They also found that prehy-

pertensin was present only in blood globulins and
that the latter could not be replaced by the other
2?

proteins in the body.
How~ver, subsequent studies with pepsin
36

by Croxatto and Croxatto have shown that pepsin
will produce a vasoconstrictor substance when allowed to act on blood glood globulins and that this
substance produced by the interaction of these two
is chemically and pharmacologically identical with
prehypertensln .

This has been confirmed by a num-

ber of other workers, among them being Page.
Ss to the reaction between renin and pre-

angiotonin, this seems to be enzymatic ~s indicated
by the following known properties of these partici3?

pants and the characteristics of the reaction itself:
l. Renin is a protein, probably a pseudoglobulin.
2. Renin is non-dialyzeble and thermolabile (destroyed above 56° C.)
3. Only a small amount of renin is necessary in proportion to the amount of blood
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substrate, and the amount of ~ngiotonin
formed is proportional to the amount of
blood globulins.
4. The reaction is affected by tempe~ature hastened by incubation at 37° C and
retarded or stopped at o C.

5. The substrate in the blood is also a
protein, non-dialyzable and thermolable
(same as 27)
6. The end product of the reaction, angiotonin is dialyzable and thermostable,
which indicates that the reaction is disiritegrative rather than integrative.

?. The fact that renin, evidently a ·
proteolytic enzyme, may be actually replaced by pepsin, ·a known proteolytic
enzyme, is further proof of the disin tegrative reaction.
As mentioned before by the ipteraction of
renin and preangiotonin there is formed a third
substance namely, angiotonin (hypertensin) which . is
the direct vasoconstrictor and presser substance
causing increase in blood pressure when injected into animals.

This substance has .not been completely

isolated but nevertheless many of its physical and
chemical properties have been demonstra ted.

It

he.a been found to heat and acid stable, water and
alobhol soluble, fluorescent, alkali l abile and
gives a color reaction for argininine.

Its presser

effect is immediate, the maximum rise ab r upt and
the entire period of elevation of blood pressure brief.
Up to this point, Page and his collaborators and
the South American group agree but from here on
- 20 -

38

their two views differ,

Page thinks that in the bo-

dy angiotonin needs an activator in order to exert its presser effect.

He deduced this from his

observations on Tachyphyloxis appearing in animals
injected with angiotonin and the fact that angiotonin was destroyed when incubated with ~enin.

The

South Americans however, do not agree with Page on
this latter pOintp for they believe a specific enzyme is present in the blood serum which destroys
angiotonin.

Early in the course of their studies

they discovered that normal blood serum would de stroy hypertensin in vitro and they adv anced the name
"hypertensinase" for the reponsible destructive agent.

They demonstrated that hypertensinase, which

was destroyed by heat (60° C) could be separated
from renin and prehypertensin, both of which are
also hea t labile, by incubating at 3?° Cat a PH of
3.9 for fifteen minutes.

Thus they showed that if

the hypertensinase in renin and serum were first destroyed by this method, which leaves renin and prehypertensin unaltered, prolonged contact of renin
a nd prehypertensin then resulted in a maximum yield
of hypertensin which remained constant despitb the
length of incubation.

The optimum PH of hyperten-

sinase activity was found to be between ?.5 and 8.5
and its action to be affected by temperature, for
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at oo Cits action stops.
an enzyme.

39

Thus they believe it to be

These investigators thus disproved Page's

assumption that angiotonin needed an activator in order
to exert its presser effect.

They showed that when

highly purified renin did not cause destruction of
antiotonin .

In their studiP-s they found that a renal

extract of toad and snake contained no demonstrable
renin but hypertensin (angiotonin) is still effective
in raising the blood pressure in both snake and toad.

40

Thus, they concluded that angiotonin is the end product
of the reaction between renin and renin-activator and
furthur indicate that there is no need for angiotoninactivator.
That the kidney may be the main source of
hyperte.n sinase in the kidney is indicated by the finding that there is almost a complete disappearance of
hypertensinase from the blood stream of bilaterally
nephrectomized dogs.
The idea that the normal kidney plays a part
in the elimination of the "chemical mediator" in exper41

mental hypertension was studied by Katz and Rodbard,
who confirmed the fact that the blood pressure falls
to normal tn six hours after the removal of a single
ischemic kidney and also observed that it takes five
times as long for it to reach normal after removal of
both kidneys when one or both were ischemic.

They

believed that the more rapid fall of the blood pressure
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to normal levels in the presence of normal kidney
tissue, as contrasted with the slow fall in its
absence, might be due to the excretion or in vivo
destruction of the "chemical Mediabor" by the remaining normal kidney.

By construction a uretero-

venous fistula on the side of the normal kidney they
showed that removal of the opposite ischemic kidney
was still followed by a rap id, six hour fall of the
blood pressure to normal and concluded that the normal renal tissue destroyed the

11

chemical mediator 11

since its excretion back into the blood stream would
have kept the blood pressure elevated for a length of
time compa rable to that necessary in the absence of
42
any renal tissue . Since then, Dexter and Braun-Menendiz have demonstrated that the renal thrshold of
renin is too high for excretion of renin to account
43

for the stabilizing role of the normal kidney.
Along this same line Friedman demonstrated
that renal vein blood from an ischemic dog's kidney
contained much less hypertensinase that renal vein
44

blood from normal kidneys.

This throws light on

the earlier experiments by freeman who found that
normal dog's blood would reduce the blood pressure of
dog's hypertensive due to constriction of the main
renal arteries, wherea s blood from hypert.ensive dogs
gave no such effect.

In this case the antipressor

effect may have been due to the presence of hyperten-
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sinase in normal blo od and its diminution in the blood
of hypertensive animals, just as other previously cited
results in bilaterally nephrectomized animal may have
been due to the absence of hypertensinase in this condition .
Another important discovery that indicates
the part which the kidney might play in the elaboration
of at least one of the substances involved in the humoral mechanism of hypertension has been given by a series
45

of i mportant studies by Bing and Collaborators.

They

have demonstrated that the ischemic kidney is capable
by effecting decorboxylation, of converting 1-dopa,

(

(1-dihydroxyphenylalanine) a substance with no presser
properties in to hydroxytramine, a powerful presser
substance.

On the contrary, 1-dopa added to normal

blood being perfused through a kidney with normal blood
flow was not converted into hydroxrtramine.

It is of

special signigicance that although liver and intestine
also contain 1-dopa-carboxylase, yet these organs were
unable, even when their circulation was reduced, to
produce hydroxytyramine from dopa added to the blood.
However, as a result of these studies Bing has not
concluded t"hat hydroxytyramone is the cause of or is in
any way involved in, the pathogenesis of experimental
renal hypertension for he hks demonstrated that angiotonin is destroyed by a different fraction of renal
extract than is hydroxytyramine, and that these two

presser substances are destyoyed by different mechanisms.
This fact, along with this finding that renin was unable
to effect decarboxylation of dopa and convert it to
hydroxytyramine, helps to emphasize Bing's contention
that he does not claim that hydroxytyramine is the cause
of experimental renal hypertension.

All he was trying

to show wa.s that when the blo od flow to a kidney has
been reduced the organ behaves differently than when
the circulation is normal, and that under these conditions it is cabable of converting an amino acid, itself
without presser properties, into a powerful presser
ag ine.

SUMMARY
It has been demonstrated that after constriction of the main renal arteries to a sufficient degree
to produce experimental renal h·y pertension, ~enin, an
enzyme, is liberated into renal vein blood.

It has

been shown that this enzyme, renin, interacts with preangiotonin (prehypertensin) a ps eudoglobulin substrate
in systemic blood, probable produced by the liver in the
presence of an adequate amount of functioning adrenal
cortical tissue, to form the final effector vasoconstrictor and presser substance, angiotonin (hypertensin).
It has also been demonstrated that the physiological
effects of the intravenous injection· of renin are identical to the hemodynamoc alterations found in experimental renal hypertension and in human essential hyperten-
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sion.

It follows, therefore, that the humeral mechanism

noted above may Rlso be responsible for the elevated
blood pressure in human essential hypertension.

Although

the demonstration in hypertensive blood of vasoconstrictor substances which may possible be related to this humoral mechanism, has beeri reported, the proof that angiotonin is the responsible agent, awaits its isolation from
the systemic blo od of human beings with hypertension.
In additi~n to renin, preangiotonin (prehypertensin) and angiotonin (hypertensin) which are involved in the humeral mechanism of experimental renal hypertension, a fourth factor, hypertensina s e (an$iotoninase)
has been discovered.

Al thou_gh this subst,ance, an enzy-

me destroys angiotonin (hypertensin) in vitro, there
is no proof yet available that it is ef f ective in lowering blood pressure in man or animals with hypatension.
It has not yet been shown that the antipressor rena~
extracts with which hypertension is said to have been
I

lowered in man and animals are rich in hypertensinase
and inactive when this enzyme is destroyed.

The exact

nature of the effective substance in antopressor renal
extracts which have been used in the treatment of hypertension, remains to be elucidated.
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Chapter III

TREATMENT OF HYPERTENSION
The treatment of essential hypertension has
heretofore been very unsatisfactory.

Too often the

therapeutic efforts are focused entirely on ways and
means of lowering the blood pressure, whereas they
should be tempered by the evidence indicating that essential hypertension is but a symptom of renal vascular disease, which is, in turn, one manifestation of
human arteriosclerosis.

Therefore the therapeutics of

essential hypertension is fundamentally that of arter4

iosclerosis.

The more accurate information we have re-

gard i ng such questions as the etiology of the disease,
i ts natural course, i ts amenability to any form of
treatment at present available, the more rational will
be the treatment the patient receives.

THE ASYMPTOMATIC PATIENT
It is to be emphasized that many individuals
with essential hypertension not only need no treatment
whatsoever, but are much better off without it.

It is

well known that many hypertensive ·patie nts carr y on
in a normal way for years until they learn of their elevated blo od pressure.

To institute a sensible regime

of living to the end that the patient attains moderation in all things is the first consideration.

An ef-

fort should be made to dispel any phobias engendered
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by previous mismanagement.

He should be told something

of the nature of his disease and should not be told of
future complications such as heart failure or cerebral
accident.

Moderation, then, is the watchword and should

be applied to occupation, mental hygiene, vacations, exercise, diet, alcohol, tobacco, coffee, tea, and obesity.
HYPERTENSIVE PATIE NTS WITH SYMPTOMS
Various therapeutic measures that have been
used in the treatment of essential hypertension a.nd which
are all directed at lowering the elevated blood pressure
include diet, mental and physical rest, drugs, organ extracts, physiotherapy, venesection, and surgery.
Diet - the two dietary measures at present
used most widely are protein and salt restriction.

Pro-

tein restriction has been popular inasmuch as one theory
of etiology names the kidney as a prima ry factor.

How-

ever, there seems to be no adequate justification for
the rigid restriction of protein in the diet of the patient with essential hypertension as long as renal function is adequate.

Salt restriction has also been used

and good results have been reported although in most
cases little or no effect is produced.
Mental and Physical Rest - mental and physical rest are probably the best means for lowering the
blood pressure in es sential h ypertension.

The influ-

ence of rest on essential hypertension is often dem- 28 -

onstrated by the notably lower blood pressure in the
morning.

In the hospital, the highest bllod pressure

is usually found on admission, and it often declines
very considerably as the patient stays in bed.

In the

malignant phase of essential hypertension in relatively
young individuals and in long-standing cases with severe arteriolosclerosis, bed rest has practically no
effect on the blood pressure.
Best results from rest are obtained when mental rest as well as physical rest are accomplished.

Bus-

iness worries, family troubles, etc., should be forgotten - an ideal not often attained in practice.

Us-

ually, the maximum drop in blood pressure, if there is
any at all, is obtained within a week or ten days, after which it stays at that level while the patient remains in bed.

Unfortunately, the blood pressure usu-

ally ascends to its previous level within a relatively
short time after the · patient returnR to his occupation.
There would seem to be no good reason for ordering
bed-rest in an individual who is accidentally found to
have high blood pressure but complains of no symptoms.
On the other hand, in cases in which there are evidences of bEgl..nning myocardial insufficiency or such
symptoms as great nervousness, headaches, dizzyness,
etc., a period of bed-rest will often produce great
improvement which often will persist for a long time
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or i ndefini tely after the blood press ure has ret urned
to its previous level.
Organotherapy - ovarian, thyroid, liver, and
pancreatic extracts have been used in the treat ment
of essential hypertension without strik i ng results.
The use of kidney extracts will be di s cussed in the
next chapter.

Ovarian extracts have been used in es-

sential hypertension starting about t h e time of the menopause, though without results as mentioned above.

Oc-

casional symptoma.tic impr ovement is seen after administration of small doses of thyroid extract in obese
women with clima cteric hypertension a nd stigmata of myxedema.

As a r ule, however, the blood pressure is

not effected by thyroid medication.

Various results

have been reported from administration of liver extracts.

The extract is slightly toxic and is adminis-

tered either intravenously, intramuscularly, or subcutaneously.

B~st results were obtained in relatively

~oung patients without marked arteriosclerosis or renal dama ge.

With this medication the blood pressure

was temporarily reduced in some patients while others
scarcely responded at all.

Pancreatic preparations

have been used in the treatment of essential hypertension and claims of blood pressure reduction have been
made although further proof is want i ng.
Venesection - the effect of venesection on
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elevated blood pressure in man is but slight; it is not
notably lowered by the abstraction of such volumes of
blood as can be removed for therapeutic purposes.

Thus,

venesection is of little or no use as a means of lowering elevated arterial tension.

However, it is a val-

uahle therapeutic aid in many instances of cardiac failure in essential hypertension - particularly with the
symptom of cardiac asthma - as well as in some of the
extremely violent headaches of hypertensive disease that
resist all other measure.
Drugs - many drugs have been used in the treatment of essential hypertension in an effort to lower
the elevated blood pressure.

Some have been proven to

be benefic i al while many have been cast into the discard.
Sedatives have long been used and have often
been of great benefit to the patient especially when
applied to proper mental and physical r e st therapy.

In

anxious, worried, and irritable patients some drop in
blood pressure is frequently observed and the nervous
symptoms are often improved.

Bromide s, chloral hydrate,

blood pressure is frequently observed and the nervous
symptoms are often improved .

Bromides, chloral hydrate,

and barbituric acid derivatives, notably . barbital and
phenolbarbi tal, are among the most useful sedative drugs
in hypertensive patients.

Gruber, Shackelford, and
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Ecklund found that in doses up to l½ grains three times
a day, phenolbarbital decreased the blood pressure 1n
85 per cent of hypertensive patients, but it usually
became less effective on prolonged admillllistration.

Bro-

mide and chloral combinations may be given to nervous
patients or bromides three times a day and phenolbarbital at night may be given; such combinations are the
most generally valuable methods of admi nistering sedatives in essential hypertension.
Nitrites and nitrates are perhaps the most
universally used drugs in the treatment of essential
hypertension.

They are reduced to nitrites in the body

and they dim i nish blood pressure by peripheral vasodilatation.

Amyl nitrite (2 to 5 minims by inhalation),

nitroglycerin (1-100 grain), erythrol tetranitrate (0.5
to 1 grai n), and sodium nitrite (1 grain) are the most
widely used.

Amyl nitrite inhalation acts within ten

or fifteen seconds but the action is over in seven minutes; sodium nitrite acts in about five minutes and
the blood pressure returns to normal in an hour or two;
nitroglycerin acts within a minute, and the action
lasts about a half-hour; erythrol tetranitrate acts
in a half-hour and the effect lasts about five hours.
Amyl nitrite is administered usually in cases of angina pectoris, but the others are often used over protra cted periods .
The therapeutic value of ni trities in essen-
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tial hypertension, 1n general, is small save in cases
with angina pectoris or certain varieties of headache.
In the malignant phase of essential hypertension they
have little or no effect.

The effect on the blood pres-

sure is too transitory and often too slight to be of
any notable value.

In many instances the nitrites, par-

ticularly erythrol tetranitrate, produce headache so
severe as to force their discontinuance.

Paradoxically,

nitrites relieve headache in other cases of essential
hypertension.
The thiocyanates were introduced into the
4

tre a tment of arteriosclerosis and hypertension by Pauli.
The ability of sodi um and potassium sulfocyanate to
lower excessively high pressures was early established
and their failure to come into wider - use was undoubtedly attributable to toxic effects of overdosage.

The

margin between toxic and therapeutic doees is not great
so that, until a simple means.of determining the sulfocyanate in the blood became available, therapy was
difficult and frequently had to be abandoned.

In recent

years sulfocyanate therapy has come into increasingly
wide use, largely as a result of the development of a
relatively si mple test to control sulfocyanate dosage.
48

Barker, in 1936, stated that blood pressure
could be reduced and symptoms alleviated in more than
50 per cent of cases, provided criteria for proper cyan-

- 33 -

ate control were observed.

Maintenance of a bllod cyan-

ate concentration between 8 and 12 mg. per hundred
cubic centi meters has brought about general clinical improvement and reduction of blood pressure (30 to 60 mm.
sysolic, and 20 to 42 mm. diastolic) in nearly 50 per
cent of 246 of Barker's cases.

Recently similar results

have been reported in the use of thiocyanate tllrapy.
Thiocyana te is thought to act in reliev i ng arteriolar
spasm and is effective unless arteriolar narrowing is
caused by organic change.

Arteriol ar sclerosis is

frequently found in patients failing to respond to thiocyanate therapy.
An initial da ily dose of 5 grains of potas-

sium or sodium sulfocyana te is usually satisfactory
f or most patients.

It shouJd be emphasized tha t the

patients' response to sul f ocyana te dosage must always ·
be the f i nal and most important criterion controlling
dosage.

Det erm i n ation of bl ood cyanate should be done

at t he end of the first week of therapy.

If the blood

level is under 6 mg. per hundred cubic centimeters, dosa ge of the drug may be doubled provided the blood pressure ha s not already shown a ma rked drop.

Sulfocyanate

dosage may have to be varied at interv als throughout
therapy dependi ng on the blood pressure level, the presence or absence of toxic symptoms, and the blood cyanate
level.

Ordinarily a blood cyanate level ranging between

8 end 12 mg . per hundred cubic centimeters is safe and
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effective.
Dangerous toxic manifestations may follow uncontrolled sulfocyanate therapy with blood cyanate levels exceeding 20, 30 or over 40 mg. per hundred cubic
centimeters.

Hemiplegia, marked delirium, and hallu-

cina tions have been encountered.

Other signs and

symptoms include depression, confusion, disorientation,
word aphasia, slurring speech, and unsteady gait.

Der-

matitis is a frequent manifestation of overdosage.
Patients likely to respond most favorably to
sulfocyanate therapy according to Barker, are those
whose red cell count is high, whose sedimentation rate
is low, and whose hypertension is the fluctuant type.
Least benefits may be expected in those with progressing anemia, rising sedimentation rate and high fixed
pressure.

Even though the latter type does poorly un-

der all kinds of treatment, an occasional patient with
malignant hyper t ension may show definite and prolonged
improvement.
tried.

Sulfocyana te threapy may, therefore, be

Special precautions should be t8ken to prevent

overdosage in these patients.
Physiotherapy - physiotherapeutic measures
such as the high frequency current, diathermy, sweating
procedures, hyperventilation by systematic deep breathing exercises, and oxygen inhalations have been used in
the treatment of hypertension with but slight effect.
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Surgery - on the whole the medical treatment
of hypertension has been unsatisfactory; drugs available
for the reduction of blood pressure usually p:ssess unpleasant side effects or are of short action.

The sur-

gical treatment of hypertension is based cl1efly on the
assumption that the increased arteriolar tone can be
released by operation on the s ympathetic nervous system,
thus lowering the blood pressure.

Extensive sympa-

49

thectomy produces two other effects of value in the
treatment of hypertension - namely, an increase in the
blood supply to the kidneys and prevention or diminution
of spontaneous release of adrenaline from the suprarenal
glands.

Whether extensive sympathectomy is more valu-

able in the treatment of essential hypertension than
partial sympathectomy, such as supradiaphragmatic splanchnicectomy (Peet) or coeliectomy (Crile), is not known,
but it seems more logical, for it relieves sympathetic
control of the kidneys and the suprarenal glands as
well as that of the intra-abdominal regions and of a
large portion of the lower extremities.

The operative

mortality is negligible in properly selected cases,
and, although some of the pRtients eventually die of
the disease, operation seems neither to have hastened
or to have delayed death.
The operation of choice at the Mayo Clinic

50

for the treatment of essential hypertension is section
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of the major, minor, and lesser splanchnic nerves, with
partial resection of the celiac ganglions and resection of the upper lumbar sympathetic ganglions.

Blood

pressure was found to be reduced considerably in 13 per
cent of a series of cases and was reduced moderately in
18 per cent; the symptoms were relieved in approximately 80 per cent, regardless of the effect on blood
pressure.

Sympathectomy is not the answer for a spec-

ific treatment of hypertension, but because of the small
risk involved and the number of excellent results obtained by the operation, it is a .worth-while procedure
in certain carefully selected cases.

Patients are

selected for sympathectomy according to the following criteria:

operation is advised only for patients

whose blood pressure responds satisfactorily to the following tests:

(1) slow and intermittent intravenous

injection of a 5 per cent solution of _pentothal sodium to a stage at which decrease in the blood pressure
no longer occurs (ordinarily 500 mg. to 1 gm. is injected ); (2) Administration of 3 arains of sodium
amytal each hour for three successive hours; (3) Administration of½ grain of sodium nitrite at half-hour
intervals until six doses have been given and (4) hourly d eterm i nation of blood pressure dur i ng rest and sleep
for a minimum of 24 consecutive hours.

If the blood

pressure decreases to normal or nearly so as a result
of all these measure, the patient may be considered a
- 3!7 -

satisfactory risk for operation.
In addition to the unfavorable res ponse of
the blood pressure, contraindications to operation
are as fol l o.vs:

age greater than fifty years, conges-

tive heart failure, angina pectoris, marked renal insuffic i ency and advanced arteriosclerosis,

Spasm and

apparent sclerosis of the retinal arteries, moderate
enlargement of the heart, inversion of T waves in the
electrocardiogram, albuminuria, and slight reduction
in renal function or a cerebrovascular accident from
which recovery has been satisfactory are not in themselves contraindications to operation.

KIDNEY EXTRACTS I N THE TREATMENT OF HYPERTENSION
The relationship of the kidney and kidney
extracts today occupy the center of interest in the
treatment of h ypertension.

Experimental trends, much

as a result of Goldblatt 1 s experimental production of
renal hypertension, are focused toward the renal presser sy s tem.

Much of this work is being carried on by

two independent groups - Page, Helmer, Kohlstaedt, Fouts,
Kempf, and Corcoran in Indi anapolis and Braun-Menendez,
Fasciolo, Leloir, and Munoz in Argent i an.

Both groups

have been seeking a presser agent which could cause
hypertension in man and both have reached simultaneous-

.

ly much the same conclusions although by di f ferent
points of attack •
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Attempting the purification of presser k1d51

ney extracts, that is, renin, Page concluded that it
was not 1n itself vasoactive but that it became active
only when in contact with a substance present in plasma.

This he called renin activator.

Renin activator

implies merely that renin is inactive in the absence of
this special protein contained in the blood.

He also

concluded, as did the South American workers, that the
presser substance was not renin itself but a third substance formed as the result of interaction of renin and
renin activator.

This third substance proved to be

a heat stable, dialysable material with strong presser properties and was called "angiotonin" by Page and
52

Helmer and "hypertensine" by the South Americans.

Ren-

al extracts, containing renin and renin activator, were
shown not only to liberate angiotonin or hypertensine
but to also go on and destroy it.

Both in Argentina

and in the United States it was shown that normal kid-

-

neys as well as other tissues contain a substance or
substances capable of destroying or ina ctivating the
presser agent (angiotonin, hypertensin e ).
Having then separated this presser substance,
angiotonin, the Indianopolis workers endeavored to
show that it had properties similar to those of a ~ubstance which could cause essential h ypertension in man
51

or renal experimental hypertension in animals.

An-

giotonin produces the kind of vasoconstriction which
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occurs in essential hypertension, a rise in arterial
pressure but no reduction in blood flow to the tissues.
This was proven by measuring the akin temperature after injection of angiotonin and by observation of the
vessels which had grown into a quqrtz chamber in the
ear of a rabbit.
The intrarenal circulation shows a characteristic change in essential hypertension; this consists
of a tendency to decreased renal blood flow and a
consistent inccease of the head of pressure within the
golmerular capillaries.

Both the efferent and affer-

ent arterioles are constricted so that the afferent
arteriole resistance protects the glomerular capillaries from the increased systemic pressure and the
efferent arteriole constriction results in back presure which is probably the origin of the increased intraglomerular pressure.

These changes were found to
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be reproduced by angiotonin in dogs and man.

Angiotonin, as in essential hypertension,
increases both the force of the heart beat and the
efficiency of the heart muscle.

Hypertensive heart

tracings and tracings of the normotensive made hypertensive by angiotonin show a striking similarity.
diac output is reduced by angiotonin as a result of
reduction in stroke volume and of pulse rate.
is a frequent finding in hypertensive patients.
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This

Caf-

A vasoconstrictor agent is present in the
blood of the renal vein, in the peripheral blood, and
following injection of renin in both experimental hypertension and naturally occuring hypertension, suggestive evidence of its being angiotonin-like in nature.
Extracts of the kidney have been prepared
which, when administered orally to normal animals, do
not produce a decline in blood pressure but have the
property of partially inhibit i ng the presser effect
of subsequently injected renin.

When extracts con-

taining the renal antipressor substance in sufficient
amount are administered, either parenterally or oral l y,
to animals with experimental renal hypertension, a
well-marked and prolonged decline in the blood pressure occurs.

Whether this is d ~sirable or undesir-

able has not yet been clearly proven.
Grollman and co-workers have treated a series of cases of hypertension with kidney extract and
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have obtained promis i ng results.

However, they state

that certain factors - effect of suggestion, a spontaneous decline in pressure, patients without renal hypertension, etc., - have not been entirely excluded
and may have been responsible for the f avorable results.
Following adm i nistration of extract, they found a wellmarked decline in blood pressure and also a relief
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of subjective symptoms.

When the administration was

discontinlEd, the blood pressure rose to the preexisting levels and the symptoms returned.
That kidney extracts contain a substance or
substances that destroy angiotonin, reduce arterial
pressure, and cause reversal of the vascular lesions
in the eyegrounds of patients exhibiting the malignant
phase seems to be evident, however, nothing is known
of the chemical properties of the substance sought.
When injected into hypertensive dogs, rats, or human
51
beings, these crude kidney extracts, according to Page,

produce a slow, progressive fall in arterial pressure
in many but not all of the subjects.

Early in the treat-

ment a slight fever may occur, which then disappears.
The fall in blood pressure is seldom to normal in humans, and the diastolic pressure is usually reduced
more than the systolic pressure.

In several weeks

regressive changes in the retinopathy occur and in several months hemorrhages, exudates and papilledema
may all have disappeared.
The mechanism of the action of kidney extracts is not understood and Page postulates that
their action is chiefly due to their ·ability to destroy angiotonin.

As evidence he sites that if an-

giotonin and kidney extract are mixed, incubated thirty minutes and boiled, and the filtrate is tested for
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presser activity on a plthed cat, angiotonases can be
estimated.
Renal extracts seem to decrease the angiotonin-like intrarenal vasoconstriction and attenuate
the progress of renal tissue de struction, probably as
a result of the decrease of arterial pressure.

Cor-

51

coran and Page found a decrease in glomerular efferent
arteriolar tone in most patients treated with kidney
extract, and an associated increase of functionally
effective renal blood flow.

As explained above, this

is just the reverse of the action of angiotonin itself.
Cardiac output is usually either normal or
decreased and the stroke volume is reduced in hypertension.

The injection of angiotonin into normoten-

sive human beings produces a similar result.

The use

of kidney extract produces a drop in blood pressure
and an increase in cardiac output.

This can be meas-

ured by the ballistocardiograph and the increased cardiac output is roughly 15 to 20 per cent.

When the

kidney extract is discontinued, the arterial pressure
rises and the cardiac output decreases to its former
level.

Thus, we have seen the results of experimentation by various groups both in this country and in
South America.

All appear to have arrived at much
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the same visualization of the role of the kidney as an
endocrine organ.

The prescription of renal H according

to Houssay and Braun-Menendez should aim at (a) suppre s sipg or diminishing the secretion of renin; (b)
destroying the renin secreted by the ischemic kidney
or indibiting its reaction with blood globulins; (c)
di minishing the amount of hypertensinogen; and (a)
preventing the action of hypertension by increasing the
amount or the activity of hypertensinase or by some
other mechanism.

Of these four aims, only the use of

kidney extract has shown any promising results.
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